Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin.

Next Previous
X
Search
Trial Profile

Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Interferons
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GUARD-C
  • Sponsors Roche

    • Most Recent Events

    • 24 Apr 2013 Recruitment completion is expected on 30 Sep 2013 according to the Iranian Registry of Clinical Trials.
    • 01 Nov 2012 Planned number of patients changed from 3000 to 4450 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top